fenofibrate and pyrroles

fenofibrate has been researched along with pyrroles in 102 studies

Research

Studies (102)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	3 (2.94)	18.2507
2000's	65 (63.73)	29.6817
2010's	33 (32.35)	24.3611
2020's	1 (0.98)	2.80

Authors

Authors	Studies
Alaupovic, P; Black, DM; Davignon, J; Heinonen, T; Leiter, L; Lupien, PJ; Ooi, TC; Shurzinske, L; Sniderman, AD; Sorisky, A; Tan, MH; Tremblay, G	1
Crook, MA; Lumb, PJ; Semra, YK; Wierzbicki, AS	1
Bairaktari, ET; Elisaf, MS; Liberopoulos, EN; Miltiadous, GA; Tsimihodimos, VK; Tzallas, CS	1
Armitage, J; Betteridge, DJ; Colhoun, H	1
Frost, RJ; Geiss, HC; Otto, C; Parhofer, KG; Schwandt, P	1
Bruckert, E; Chapman, MJ; Foglietti, MJ; Giral, P; Jacob, N; Turpin, G	1
Bairaktari, E; Elisaf, MS; Kiortisis, DN; Millionis, H	1
Bairaktari, ET; Elisaf, MS; Liberopoulos, EN; Milionis, HJ	1
Ceska, R; Haas, T; Hradec, J; Malik, J; Melenovsky, V; Simek, J; Wichterle, D	1
Delaval, D; Després, JP; Lemieux, I; Salomon, H	1
Athyros, VG; Athyrou, VV; Demitriadis, DS; Kontopoulos, AG; Papageorgiou, AA	1
Achimastos, A; Bairaktari, E; Elisaf, M; Goudevenos, J; Kakafika, A; Liamis, G; Miltiadous, G; Tsimihodimos, V	1
Ceska, R; Malik, J; Melenovsky, V; Pisarikova, A; Poledne, R; Simek, J; Skrha, J; Stavek, P; Wichterle, D	1
Lin, JH; Mu, L; Prueksaritanont, T; Qiu, Y; Subramanian, R; Tang, C	1
Ceska, R; Fialova, L; Malbohan, I; Stulc, T; Zima, T	1
Barrett, PH; Chan, DC; Croft, KD; Ji, J; Johnson, AG; Loehrer, F; Serone, AP; Watts, GF	1
Belowski, D; Herman, ZS; Kalina, Z; Kowalski, J; Madej, A; Okopień, B; Zieliński, M	1
Betz, W; Devroey, D; Duquet, W; Velkeniers, B	1
Ceska, R; Haas, T; Malik, J; Malik, M; Melenovsky, V; Simek, J; Wichterle, D	1
Khadipash, LA; Kiseleva, NV; Kosmatova, OV; Mamedov, MN; Oganov, RG; Perova, NV	1
Chasiotis, G; Elisaf, MS; Kakafika, A; Milionis, HJ; Papakostas, J; Seferiadis, K	1
Bedynek, A; Bilz, S; Demant, T; Keller, U; Schmitz, M; Wagner, S	1
Després, JP; Lemieux, I; Salomon, H	1
Dierkes, J; Güttler, K; Luley, C; Westphal, S; Wiens, L	1
Baumstark, MW; Friedrich, I; Hauck, P; Hoffmann, MM; März, W; Nickell, HH; Schmitz, H; Weltzien, P; Wieland, H; Winkler, K	1
Belowski, D; Herman, ZS; Huzarska, M; Kulach, A; Madej, A; Okopien, B; Stachura-Kulach, A; Zielinski, M	1
Haberka, M; Herman, ZS; Krysiak, R; Okopien, B	1
Alacacioglu, A; Caliskan, S; Ceylan, C; Comlekci, A; Saklamaz, A; Temiz, A; Yesil, S	1
Ahn, JY; Choi, IS; Chung, WJ; Han, SH; Koh, KK; Quon, MJ; Seo, YH; Shin, EK	1
Athyros, VG; Elisaf, M; Mikhailidis, DP	1
Athyros, VG; Didangelos, TP; Elisaf, M; Kakafika, AI; Karagiannis, A; Kleta, D; Mikhailidis, DP; Papageorgiou, AA; Peletidou, A; Tziomalos, K	1
Balice, M; Chironi, G; Del-Pino, M; Gariepy, J; Levenson, J; Simon, A	1
Davidson, MH	1
Daskalopoulou, SS; Elisaf, M; Mikhailidis, DP; Tzovaras, V	1
Celinska-Löwenhoff, M; Löwenhoff, T; Szczeklik, A; Undas, A	1
Athyros, VG; Burroughs, AK; Didangelos, TP; Elisaf, MS; Giouleme, OI; Kakafika, AI; Karagiannis, A; Liberopoulos, EN; Mikhailidis, DP; Tziomalos, K	1
Cipriano, P; Di Marino, L; Gentile, A; Iovine, C; Lilli, S; Patti, L; Riccardi, G; Rivellese, AA	1
Chiesa, G; Cippone, V; Conte Camerino, D; De Luca, A; De Vito, D; Didonna, MP; Frigeri, A; Nicchia, GP; Pierno, S; Pisoni, M; Rizzo, C; Scanziani, E; Sirtori, C; Svelto, M	1
Cariolou, M; Christidis, DS; Elisaf, MS; Ganotakis, ES; Kakafika, AI; Liberopoulos, EN; Mikhailidis, DP; Miltiadous, GA	1
Antonini, R; Antonini, TM; Arca, M; Di Angelantonio, E; Diczfalusy, U; Iuliano, L; Micheletta, F; Montali, A; Natoli, S; Riggi, S	1
Janíková, L; Stanková, B; Stopka, P; Tvrzická, E; Vareka, T; Vecka, M; Zahin, M; Zák, A; Zeman, M	1
Gomez, EV; Howey, DC; McErlean, E; Nicholls, SJ; Nissen, SE; Russo, JM; Wang, MD; Wolski, K	1
Bal, BS; Kant, R; Mahajan, M; Sharma, R; Singh, B	1
Rajshree, M; Vipul, K	1
Bauman, JN; Davis, JA; Goosen, TC; Hurst, SI; Loi, CM; Williams, JA; Yu, C	1
Badyal, DK; Calton, R; Chatley, P; Khosla, PP	1
Frost, RJ; Otto, B; Otto, C; Parhofer, KG; Pfeiffer, AF; Spranger, J; Vogeser, M	1
Benatar, JR; Stewart, RA	1
Antonini, R; Antonini, TM; Arca, M; Fraioli, A; Letizia, C; Luigi, P; Maddaloni, M; Mastrantoni, M; Montali, A; Pigna, G	1
Bergeron, J; Couture, P; Deshaies, Y; Gagné, C; Hogue, JC; Lamarche, B; Tremblay, AJ	1
Bergeron, J; Couture, P; Gagné, C; Hogue, JC; Lamarche, B; Tremblay, AJ	1
Dimitri, E; Landry, P; Légaré, N; Tessier, S	1
Barrett, PH; Chan, DC; Ji, J; Johnson, AG; Ooi, EM; Watts, GF	1
Kadav, AA; Vora, DN	1
Bays, HE; Buttler, SM; Davidson, MH; Jones, PH; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC	1
Ginsberg, HN; Ramakrishnan, R	1
Alrasadi, K; Alwaili, K; Awan, Z; Genest, J; Hafiane, A; Krimbou, L; Ruel, I	1
Saegusa, Y; Shiragami, M; Takahashi, T; Takimoto, Y	1
Ballantyne, CM; Bays, HE; Buttler, SM; Goldberg, AC; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC	1
Bianco, G; Camerino, GM; Cippone, V; Conte Camerino, D; De Luca, A; Desaphy, JF; George, AL; Kunic, JD; Liantonio, A; Pierno, S; Rolland, JF	1
Das, R; Jaydip, R; Mohan, V; Sudhakaran, C; Unnikrishnan, R	1
Antonini, R; Arca, M; Baroni, MG; Cambuli, VM; Campagna, F; Filippi, E; Montali, A; Quagliarini, F; Romeo, S; Sentinelli, F	1
Barrett, PH; Chan, DC; Ji, J; Johnson, AG; Ooi, EM; Rye, KA; Watts, GF	1
Cole, RP	1
Bai, L; Hu, M; Huang, XS; Zhang, Q; Zhao, SP; Zhao, W	1
Zdebik, AA	1
Kelly, MT; Kipnes, MS; Lele, A; Rhyne, JM; Roth, EM; Setze, CM; Sleep, DJ; Stolzenbach, JC	1
Day, A; Kumar, SS; LaHaye, SA; Lahey, KA	1
Whayne, TF	1
Beckert, M; Davidson, MH; Drucker, J; Eugene Griffin, H; Oosman, S; Rooney, MW	1
Cusi, K; Davidson, MH; Jones, PH; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC; Thakker, K	1
Abel, R; Alvey, C; Bullen, W; Hartman, D; Porcari, AR; Whitfield, LR	1
Bachowski, R; Gdula-Dymek, A; Krysiak, R; Okopien, B	1
Cariou, B; Costet, P; Guyomarc'h Delasalle, B; Hoffmann, MM; Konrad, T; Winkler, K	1
Goldberg, AC; Jones, PH; Kelly, MT; Knapp, HR; Setze, CM; Sleep, DJ; Stolzenbach, JC	1
Agrogiannis, G; Iliopoulos, DG; Karatzas, G; Mikhailidis, DP; Pantopoulou, A; Paraskevas, KI; Perrea, DN; Tzivras, D; Vlachos, IS	1
Cho, EJ; Kim, CJ; Kim, JE; Kwon, JE; Min, YJ; Oh, MS	1
Puszczewicz, M; Ruchala, M; Sosnowski, P; Sowinski, J; Szczepanek, E	1
Ballantyne, CM; Jones, PH; Kelly, MT; Lele, A; Setze, CM; Stolzenbach, JC; Thakker, KM	1
Kelly, MT; Mohiuddin, SM; Setze, CM; Thakker, KM	1
Chen, ZY; Lei, L; Li, LY; Liu, Q; Liu, SN; Shen, ZF; Zhang, N	1
Karska-Basta, I; Kubicka-Trząska, A; Romanowska-Dixon, B; Undas, A	1
Bielecka, A; Bułdak, Ł; Duława-Bułdak, A; Krysiak, R; Madej, A; Okopień, B; Łabuzek, K	1
Bandgar, TR; Faruqui, AA	1
Filippatos, TD	1
Ballantyne, CM; Carlson, DM; Davidson, M; Maki, KC; Nicholls, SJ; Rosenson, RS; Setze, C; Stolzenbach, J	1
Ballantyne, CM; Belmont, JW; Brautbar, A; Keinan, A; Ma, L	1
Barrett, PH; Chan, DC; Ng, TW; Ooi, EM; Watts, GF	1
Buldak, L; Dulawa-Buldak, A; Labuzek, K; Okopien, B	1
Dhull, P; Kumar, KV; Patnaik, SK; Upreti, V	1
Brown, E; Crane, HM; Delaney, JA; Eron, JJ; Hunt, PW; Kahn, JO; Kitahata, MM; Liu, W; Mathews, WC; Mugavero, MJ; Muñoz, MA; Napravnik, S; Saag, MS; Willig, JH	1
Droog, S; Havekes, LM; Maas, AC; Offerman, EH; Pieterman, EJ; Princen, HM; van den Hoek, AM; van den Hoogen, RM; van der Hoorn, JW; van Nieuwkoop, A	1
Aramin, H; Eslami, L; Malekzadeh, R; Merat, S; Nasseri-Moghaddam, S	1
David, DC; Haribalaji, N; Harivenkatesh, N; Sudhakar, MK	1
Kapoor, A; Kumar, S; Rai, H; Sinha, N; Tewari, S	1
Elisaf, M; Kei, A; Liberopoulos, E; Tellis, C; Tselepis, A	1
Ballantyne, CM; Camp, HS; Carlson, DM; Davidson, MH; Kelly, MT; Lele, A; Maki, KC; Mazzone, T; Nicholls, SJ; Rosenson, RS; Stolzenbach, JC; Williams, LA	1
Angus, PW; Ekinci, EI; Gow, PJ; Jones, RM; O'Brien, RC; Page, MM	1
Jacob, RF; Mason, RP	1
Bhattacharjee, S; Das, N; Mandala, A; Mukherjee, B; Mukhopadhyay, S; Roy, SS	1
Bhoi, B; Das, N; Giri, SR; Jain, MR; Kadam, S; Karmakar, E; Patel, H; Patel, PR; Ranvir, R; Rath, A; Rathod, R; Roy, SS; Swain, P; Trivedi, C; Wahli, W	1
Cruz-López, P; González, JG; Parmar, D; Rodriguez-Gutierrez, R; Shaikh, F	1

Reviews

6 review(s) available for fenofibrate and pyrroles

Article	Year
Reducing residual risk for patients on statin therapy: the potential role of combination therapy. The American journal of cardiology, 2005, Nov-07, Volume: 96, Issue:9A Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Pyrroles; Risk Factors	2005
Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia. Current pharmaceutical design, 2005, Volume: 11, Issue:32 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Fenofibrate; Heptanoic Acids; Humans; Losartan; Pyrroles; Uric Acid	2005
Is it time to stop treating dyslipidaemia with fibrates? The New Zealand medical journal, 2007, Sep-07, Volume: 120, Issue:1261 Topics: Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Pyrroles; Randomized Controlled Trials as Topic	2007
A review of time courses and predictors of lipid changes with fenofibric acid-statin combination. Cardiovascular drugs and therapy, 2012, Volume: 26, Issue:3 Topics: Atorvastatin; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2012
Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. The Cochrane database of systematic reviews, 2013, Dec-27, Issue:12 Topics: Alanine Transaminase; Atorvastatin; Fatty Liver; Fenofibrate; gamma-Glutamyltransferase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Non-alcoholic Fatty Liver Disease; Pyrroles; Simvastatin	2013
Liver transplantation for the treatment of homozygous familial hypercholesterolaemia in an era of emerging lipid-lowering therapies. Internal medicine journal, 2014, Volume: 44, Issue:6 Topics: Adult; Atorvastatin; Azetidines; Blood Component Removal; Cholesterol, LDL; Combined Modality Therapy; Consanguinity; Coronary Artery Bypass; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Fenofibrate; Heart Valve Diseases; Heart Valve Prosthesis Implantation; Heptanoic Acids; Homozygote; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoproteins, LDL; Liver Transplantation; Male; Pyrroles; Receptors, LDL	2014

Trials

58 trial(s) available for fenofibrate and pyrroles

Article	Year
Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: comparison with fenofibrate. Arteriosclerosis, thrombosis, and vascular biology, 1997, Volume: 17, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Diet; Female; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Safety	1997
High-dose atorvastatin therapy in severe heterozygous familial hypercholesterolaemia. QJM : monthly journal of the Association of Physicians, 1998, Volume: 91, Issue:4 Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholestyramine Resin; Drug Administration Schedule; Drug Combinations; Fenofibrate; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Middle Aged; Pyrroles; Simvastatin; Triglycerides	1998
Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia. Journal of cardiovascular risk, 1999, Volume: 6, Issue:2 Topics: Adolescent; Adult; Aged; Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Female; Fenofibrate; Fibrinogen; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoprotein(a); Male; Middle Aged; Pyrroles; Treatment Outcome; Triglycerides	1999
Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia. The American journal of cardiology, 2001, Jan-01, Volume: 87, Issue:1 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Fenofibrate; Hemorheology; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Prospective Studies; Pyrroles; Statistics, Nonparametric	2001
Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia. Atherosclerosis, 2001, Feb-01, Volume: 154, Issue:2 Topics: Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Chromatography, High Pressure Liquid; Cysteine; Dipeptides; Female; Fenofibrate; Heptanoic Acids; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type V; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Triglycerides	2001
Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia. European journal of clinical pharmacology, 2000, Volume: 56, Issue:9-10 Topics: Adolescent; Adult; Aged; Atorvastatin; Cholesterol; Drug Combinations; Female; Fenofibrate; Fibrinogen; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Triglycerides	2000
Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial--FAT). Cardiovascular research, 2001, Volume: 52, Issue:2 Topics: Adult; Arm; Atorvastatin; C-Reactive Protein; Case-Control Studies; Cholesterol, HDL; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Image Processing, Computer-Assisted; Male; Middle Aged; Muscle, Smooth, Vascular; Pyrroles; Regional Blood Flow; Regression Analysis; Triglycerides; Ultrasonography, Doppler, Duplex	2001
Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL-cholesterol levels: a 12-week randomized trial. Journal of internal medicine, 2002, Volume: 251, Issue:6 Topics: Atorvastatin; Cholesterol, HDL; Coronary Disease; Female; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles	2002
Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes care, 2002, Volume: 25, Issue:7 Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Blood Glucose; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Fenofibrate; Fibrinogen; Heptanoic Acids; Humans; Hyperlipidemias; Lipoprotein(a); Lipoproteins, HDL; Male; Middle Aged; Pyrroles; Triglycerides	2002
Combined treatment with fibrates and small doses of atorvastatin in patients with mixed hyperlipidemia. Current medical research and opinion, 2002, Volume: 18, Issue:3 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Clofibric Acid; Drug Administration Schedule; Drug Therapy, Combination; Female; Fenofibrate; Fibric Acids; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type V; Hypolipidemic Agents; Lipids; Liver; Male; Middle Aged; Pyrroles; Treatment Outcome	2002
Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia. American heart journal, 2002, Volume: 144, Issue:4 Topics: Apolipoproteins B; Atorvastatin; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Fenofibrate; Fibrinogen; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Risk Factors; Triglycerides	2002
Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes, 2003, Volume: 52, Issue:3 Topics: Adult; Apolipoprotein A-I; Apolipoprotein B-100; Apolipoproteins B; Atorvastatin; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Diet; Double-Blind Method; Fenofibrate; Heptanoic Acids; Humans; Hypolipidemic Agents; Insulin; Kinetics; Lipoproteins; Lipoproteins, HDL; Lipoproteins, IDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Metabolic Syndrome; Middle Aged; Obesity; Placebos; Pyrroles; Triglycerides	2003
Effects of atorvastatin, simvastatin, and fenofibrate therapy on monocyte chemoattractant protein-1 secretion in patients with hyperlipidemia. European journal of clinical pharmacology, 2003, Volume: 59, Issue:3 Topics: Atorvastatin; Cells, Cultured; Chemokine CCL2; Enzyme-Linked Immunosorbent Assay; Female; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Middle Aged; Monocytes; Pyrroles; Simvastatin	2003
Effect of atorvastatin and fenofibrate on autonomic tone in subjects with combined hyperlipidemia. The American journal of cardiology, 2003, Aug-01, Volume: 92, Issue:3 Topics: Adult; Atorvastatin; Autonomic Nervous System; Baroreflex; Cross-Over Studies; Fenofibrate; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lipids; Male; Middle Aged; Pyrroles	2003
Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia. Journal of clinical pharmacology, 2003, Volume: 43, Issue:8 Topics: Analysis of Variance; Atorvastatin; Blood Glucose; Female; Fenofibrate; Heptanoic Acids; Homocysteine; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Simvastatin; Uric Acid	2003
Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia. Journal of lipid research, 2004, Volume: 45, Issue:1 Topics: Adult; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoprotein B-100; Apolipoproteins B; Atorvastatin; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemias; Kinetics; Leucine; Lipids; Male; Middle Aged; Pyrroles	2004
Contribution of apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients. Annals of medicine, 2003, Volume: 35, Issue:6 Topics: Adult; Aged; Anticholesteremic Agents; Apolipoprotein C-III; Apolipoproteins C; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoprotein Lipase; Male; Middle Aged; Pyrroles; Treatment Outcome; Triglycerides	2003
Chylomicron remnants of various sizes are lowered more effectively by fenofibrate than by atorvastatin in patients with combined hyperlipidemia. Atherosclerosis, 2003, Volume: 171, Issue:2 Topics: Administration, Oral; Adult; Atorvastatin; Chylomicron Remnants; Chylomicrons; Cross-Over Studies; Drug Administration Schedule; Female; Fenofibrate; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Male; Middle Aged; Particle Size; Postprandial Period; Probability; Prospective Studies; Pyrroles; Risk Assessment; Statistics, Nonparametric; Treatment Outcome	2003
Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2004, Volume: 112, Issue:5 Topics: Adult; Aged; Atorvastatin; Drug Therapy, Combination; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, LDL; Liver Function Tests; Male; Middle Aged; Pyrroles; Time Factors	2004
Effect of monthly atorvastatin and fenofibrate treatment on monocyte chemoattractant protein-1 release in patients with primary mixed dyslipidemia. Journal of cardiovascular pharmacology, 2005, Volume: 45, Issue:4 Topics: Adult; Analysis of Variance; Atorvastatin; Chemokine CCL2; Double-Blind Method; Drug Administration Schedule; Female; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Pyrroles; Statistics, Nonparametric	2005
The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia. Metabolism: clinical and experimental, 2005, Volume: 54, Issue:5 Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Erythrocyte Deformability; Female; Fenofibrate; Fibrinogen; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Pyrroles; Triglycerides	2005
Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. Journal of the American College of Cardiology, 2005, May-17, Volume: 45, Issue:10 Topics: Arteriosclerosis; Atorvastatin; Brachial Artery; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Fenofibrate; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lipids; Male; Middle Aged; Myocardial Ischemia; Pyrroles; Treatment Outcome; Ultrasonography	2005
Inflammatory markers and the metabolic syndrome. Atherosclerosis, 2005, Volume: 183, Issue:1 Topics: Antihypertensive Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Drug Therapy, Combination; Fenofibrate; Fibrinogen; Heptanoic Acids; Humans; Hypolipidemic Agents; Inflammation; Lactones; Leukocyte Count; Metabolic Syndrome; Metformin; Orlistat; Prospective Studies; Pyrroles; Treatment Outcome	2005
Targeting vascular risk in patients with metabolic syndrome but without diabetes. Metabolism: clinical and experimental, 2005, Volume: 54, Issue:8 Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Diabetes Mellitus; Drug Therapy, Combination; Female; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Metabolic Syndrome; Middle Aged; Obesity; Prevalence; Prospective Studies; Pyrroles; Risk Factors; Risk Reduction Behavior	2005
Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease. Journal of thrombosis and haemostasis : JTH, 2006, Volume: 4, Issue:5 Topics: Aged; Atorvastatin; Coronary Artery Disease; Fenofibrate; Fibrinolysis; Genotype; Heptanoic Acids; Humans; Male; Permeability; Pyrroles; Quinapril; Simvastatin; Tetrahydroisoquinolines; Thrombin; Thrombosis	2006
Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Current medical research and opinion, 2006, Volume: 22, Issue:5 Topics: Anti-Obesity Agents; Atorvastatin; Diet, Fat-Restricted; Drug Therapy, Combination; Dyslipidemias; Fatty Liver; Female; Fenofibrate; Heptanoic Acids; Humans; Hypolipidemic Agents; Lactones; Male; Metabolic Syndrome; Middle Aged; Orlistat; Prevalence; Prospective Studies; Pyrroles; Risk Factors; Treatment Outcome; Ultrasonography; Weight Loss	2006
Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia. European journal of clinical investigation, 2006, Volume: 36, Issue:8 Topics: Anticholesteremic Agents; Area Under Curve; Atorvastatin; Cholesterol; Cholesterol, LDL; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, VLDL; Male; Middle Aged; Postprandial Period; Pyrroles; Treatment Outcome; Triglycerides	2006
Increased plasma levels of oxysterols, in vivo markers of oxidative stress, in patients with familial combined hyperlipidemia: reduction during atorvastatin and fenofibrate therapy. Free radical biology & medicine, 2007, Mar-01, Volume: 42, Issue:5 Topics: Adult; alpha-Tocopherol; Atorvastatin; Biomarkers; Drug Combinations; Female; Fenofibrate; Heptanoic Acids; Humans; Hydroxycholesterols; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Ketocholesterols; Lipids; Lipoproteins; Male; Middle Aged; Models, Biological; Oxidative Stress; Pyrroles	2007
[Oxidation stress, insulin resistance and endothelial dysfunction during the treatment of hyperlipidaemia]. Casopis lekaru ceskych, 2006, Volume: 145, Issue:12 Topics: Adult; Aged; Atorvastatin; Diabetes Mellitus, Type 2; Endothelium, Vascular; Fatty Acids, Omega-3; Female; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Insulin Resistance; Male; Middle Aged; Oxidative Stress; Pyrroles; Simvastatin	2006
Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials. JAMA, 2007, Mar-28, Volume: 297, Issue:12 Topics: Atorvastatin; Double-Blind Method; Dyslipidemias; Female; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Male; Middle Aged; PPAR alpha; Propionates; Pyrroles; Triazoles	2007
Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients. Journal of the Indian Medical Association, 2006, Volume: 104, Issue:9 Topics: Adult; Apolipoproteins B; Atorvastatin; Biomarkers; Coronary Disease; Drug Administration Schedule; Female; Fenofibrate; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Nephelometry and Turbidimetry; Pyrroles; Simvastatin; Treatment Outcome	2006
Combination therapy of low-dose atorvastatin and fenofibrate in mixed hyperlipidemia. Methods and findings in experimental and clinical pharmacology, 2007, Volume: 29, Issue:3 Topics: Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Atorvastatin; Cholesterol; Creatine Kinase; Drug Therapy, Combination; Female; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Triglycerides	2007
Short-term therapy with atorvastatin or fenofibrate does not affect plasma ghrelin, resistin or adiponectin levels in type 2 diabetic patients with mixed hyperlipoproteinaemia. Acta diabetologica, 2007, Volume: 44, Issue:2 Topics: Adiponectin; Aged; Atorvastatin; Body Mass Index; Body Weight; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Fenofibrate; Ghrelin; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemias; Hypolipidemic Agents; Male; Middle Aged; Peptide Hormones; Pyrroles; Resistin	2007
Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia. Metabolism: clinical and experimental, 2007, Volume: 56, Issue:11 Topics: Adult; Aged; Atorvastatin; Biomarkers; Endothelin-1; Endothelium, Vascular; Female; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles	2007
Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia. Metabolism: clinical and experimental, 2008, Volume: 57, Issue:2 Topics: Anticholesteremic Agents; Apolipoprotein B-100; Apolipoprotein B-48; Atorvastatin; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind Method; Fenofibrate; Heptanoic Acids; Humans; Hypertriglyceridemia; Kinetics; Leucine; Male; Middle Aged; Pyrroles; Triglycerides	2008
Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus. Metabolism: clinical and experimental, 2008, Volume: 57, Issue:3 Topics: Atorvastatin; Biomarkers; Cell Adhesion Molecules; Diabetes Mellitus, Type 2; Female; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Inflammation; Lipids; Lipoproteins; Lipoproteins, LDL; Male; Middle Aged; Oxidation-Reduction; Pyrroles	2008
Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome. Arteriosclerosis, thrombosis, and vascular biology, 2008, Volume: 28, Issue:10 Topics: Adult; Apolipoprotein C-III; Apolipoproteins A; Apolipoproteins B; Atorvastatin; Cholesterol; Cross-Over Studies; Double-Blind Method; Down-Regulation; Dyslipidemias; Fenofibrate; Gas Chromatography-Mass Spectrometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kinetics; Lipoproteins, VLDL; Male; Metabolic Syndrome; Middle Aged; Models, Biological; Pyrroles; Treatment Outcome; Triglycerides	2008
Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme. Clinical drug investigation, 2008, Volume: 28, Issue:10 Topics: Analysis of Variance; Atorvastatin; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Prospective Studies; Pyrimidines; Pyrroles; Research Design; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome	2008
Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. The American journal of cardiology, 2009, Feb-15, Volume: 103, Issue:4 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Treatment Outcome; Triglycerides	2009
Regulatory effects of fenofibrate and atorvastatin on lipoprotein A-I and lipoprotein A-I:A-II kinetics in the metabolic syndrome. Diabetes care, 2009, Volume: 32, Issue:11 Topics: Atorvastatin; Cross-Over Studies; Double-Blind Method; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kinetics; Lipoprotein(a); Lipoproteins, HDL; Male; Metabolic Syndrome; Nephelometry and Turbidimetry; Placebos; Pyrroles	2009
Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study. Clinical drug investigation, 2010, Volume: 30, Issue:1 Topics: Adult; Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, VLDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2010
Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia. Lipids in health and disease, 2009, Dec-17, Volume: 8 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Demography; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fenofibrate; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Time Factors; Treatment Outcome; Young Adult	2009
Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study. Clinical therapeutics, 2009, Volume: 31, Issue:12 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Atorvastatin; Biomarkers; Cardiovascular Diseases; Cholesterol; Double-Blind Method; Drug Combinations; Dyslipidemias; Female; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Inflammation Mediators; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Tablets; Time Factors; Treatment Outcome; Triglycerides; United States	2009
Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin. Journal of clinical pharmacology, 2011, Volume: 51, Issue:3 Topics: Adult; Atorvastatin; Biotransformation; Cross-Over Studies; Drug Interactions; Enzyme Inhibitors; Female; Fenofibrate; Gemfibrozil; Half-Life; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lactones; Male; Middle Aged; Pyrroles	2011
Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of pre-diabetes. Diabetes care, 2010, Volume: 33, Issue:10 Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cytokines; Factor VII; Fenofibrate; Fibrinogen; Heptanoic Acids; Humans; Metabolic Syndrome; Plasminogen Activator Inhibitor 1; Prediabetic State; Pyrroles	2010
Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients. Atherosclerosis, 2010, Volume: 212, Issue:1 Topics: Adult; Aged; Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; France; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Proprotein Convertase 9; Proprotein Convertases; Pyrroles; Serine Endopeptidases; Time Factors; Treatment Outcome; Triglycerides; Up-Regulation	2010
Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia. American heart journal, 2010, Volume: 160, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fenofibrate; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Treatment Outcome; Young Adult	2010
Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides. Cardiovascular drugs and therapy, 2011, Volume: 25, Issue:1 Topics: Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides	2011
Evaluating optimal lipid levels in patients with mixed dyslipidemia following short- and long-term treatment with fenofibric acid and statin combination therapy: a post hoc analysis. Current medical research and opinion, 2011, Volume: 27, Issue:5 Topics: Atorvastatin; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Time Factors	2011
Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial. Cardiovascular drugs and therapy, 2012, Volume: 26, Issue:4 Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Carotid Arteries; Carotid Intima-Media Thickness; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Double-Blind Method; Dyslipidemias; Female; Fenofibrate; Follow-Up Studies; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Risk Factors; Triglycerides	2012
Interaction between SNPs in the RXRA and near ANGPTL3 gene region inhibits apoB reduction after statin-fenofibric acid therapy in individuals with mixed dyslipidemia. Journal of lipid research, 2012, Volume: 53, Issue:11 Topics: Angiopoietin-Like Protein 3; Angiopoietin-like Proteins; Angiopoietins; Apolipoproteins; Apolipoproteins B; Atorvastatin; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Polymorphism, Single Nucleotide; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2012
Effect of fenofibrate and atorvastatin on VLDL apoE metabolism in men with the metabolic syndrome. Journal of lipid research, 2012, Volume: 53, Issue:11 Topics: Adult; Apolipoproteins B; Apolipoproteins E; Atorvastatin; Double-Blind Method; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, VLDL; Male; Metabolic Syndrome; Middle Aged; Pyrroles	2012
Effects of 90-day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose. International journal of clinical pharmacology and therapeutics, 2012, Volume: 50, Issue:11 Topics: Adipokines; Adiponectin; Adult; Aged; Analysis of Variance; Atorvastatin; Biomarkers; Blood Glucose; Cytokines; Drug Therapy, Combination; Female; Fenofibrate; Glucose Metabolism Disorders; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type V; Hypolipidemic Agents; Inflammation Mediators; Insulin; Insulin Resistance; Interleukin-6; Leptin; Lipids; Male; Middle Aged; Poland; Pyrroles; Resistin; Risk Reduction Behavior; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha	2012
Efficacy and safety of alternate day therapy with atorvastatin and fenofibrate combination in mixed dyslipidemia: a randomized controlled trial. Journal of cardiovascular pharmacology and therapeutics, 2014, Volume: 19, Issue:3 Topics: Adult; Atorvastatin; Cholesterol; Cost-Benefit Analysis; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Triglycerides	2014
Pharmacological measures to increase HDL-C among high risk isolated low HDL cases: a randomized study amongst north Indians. The Indian journal of medical research, 2013, Volume: 138, Issue:6 Topics: Aged; Atorvastatin; Cholesterol, HDL; Coronary Disease; Female; Fenofibrate; Heptanoic Acids; Humans; India; Lipids; Male; Middle Aged; Niacin; Pyrroles; Risk Factors	2013
Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia. Cardiovascular therapeutics, 2014, Volume: 32, Issue:4 Topics: Aged; Apolipoprotein B-100; Atorvastatin; Bilirubin; Biomarkers; Dinoprost; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Greece; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Lipoproteins, LDL; Male; Middle Aged; Niacin; Oxidative Stress; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome; Uric Acid	2014
Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST). Arteriosclerosis, thrombosis, and vascular biology, 2014, Volume: 34, Issue:6 Topics: Atorvastatin; Carotid Intima-Media Thickness; Cholesterol, LDL; Double-Blind Method; Dyslipidemias; Female; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Triglycerides	2014
Saroglitazar is noninferior to fenofibrate in reducing triglyceride levels in hypertriglyceridemic patients in a randomized clinical trial. Journal of lipid research, 2022, Volume: 63, Issue:7 Topics: Adult; Double-Blind Method; Fenofibrate; Humans; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Phenylpropionates; Pyrroles; Triglycerides	2022

Other Studies

38 other study(ies) available for fenofibrate and pyrroles

Article	Year
Status report of lipid-lowering trials in diabetes. Current opinion in lipidology, 2000, Volume: 11, Issue:6 Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Pyrroles; Risk Factors	2000
Atorvastatin versus micronized fenofibrate in the treatment of patients with mixed hyperlipoproteinemia. The American journal of cardiology, 2001, Jul-15, Volume: 88, Issue:2 Topics: Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Fenofibrate; Heptanoic Acids; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Pyrroles	2001
Effects of fibrates on metabolism of statins in human hepatocytes. Drug metabolism and disposition: the biological fate of chemicals, 2002, Volume: 30, Issue:11 Topics: Aryl Hydrocarbon Hydroxylases; Atorvastatin; Cytochrome P-450 CYP2C8; Fenofibrate; Fluorobenzenes; Gemfibrozil; Glucuronosyltransferase; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; In Vitro Techniques; Microsomes, Liver; Oxidation-Reduction; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2002
PAPP-A, a novel marker of unstable plaque, is not influenced by hypolipidemic treatment in contrast to CRP. Atherosclerosis, 2003, Volume: 166, Issue:1 Topics: Atorvastatin; Biomarkers; C-Reactive Protein; Coronary Disease; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Pregnancy-Associated Plasma Protein-A; Pyrroles	2003
Serum lipid comparison in patients treated by statins or fibrates: existence of bad HDL-C responders to statins. Acta cardiologica, 2003, Volume: 58, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fibric Acids; Fluvastatin; Heptanoic Acids; Humans; Hyperlipidemias; Indoles; Male; Microfilament Proteins; Middle Aged; Muscle Proteins; Pravastatin; Pyrroles; Retrospective Studies	2003
[Effect of combined antihypertensive and lipid lowering therapy on the level of coronary risk and tissue insulin resistance in patients with metabolic syndrome]. Kardiologiia, 2003, Volume: 43, Issue:3 Topics: Adult; Antihypertensive Agents; Atenolol; Atorvastatin; Blood Pressure; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Fenofibrate; Heptanoic Acids; Humans; Hypolipidemic Agents; Indapamide; Male; Metabolic Syndrome; Middle Aged; Perindopril; Pyrroles; Simvastatin; Treatment Outcome	2003
Hypolipidemic drugs affect monocyte IL-1beta gene expression and release in patients with IIa and IIb dyslipidemia. Journal of cardiovascular pharmacology, 2005, Volume: 45, Issue:2 Topics: Atorvastatin; Cells, Cultured; Clofibric Acid; Cytokines; Fenofibrate; Fibrinolytic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Interleukin-1; Lipids; Monocytes; Plasminogen Activator Inhibitor 1; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction	2005
Differential associations of statin and fibrate treatment with carotid arterial remodeling. American journal of hypertension, 2005, Volume: 18, Issue:11 Topics: Adult; Atorvastatin; Bezafibrate; Body Mass Index; Carotid Arteries; Cholesterol, HDL; Clofibric Acid; Cohort Studies; Dyslipidemias; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fibric Acids; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Male; Middle Aged; Multivariate Analysis; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography	2005
Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: a biochemical, histological and electrophysiological study. British journal of pharmacology, 2006, Volume: 149, Issue:7 Topics: Action Potentials; Animals; Aquaporin 4; Atorvastatin; Body Weight; Chloride Channels; Dose-Response Relationship, Drug; Eating; Fatty Acids, Monounsaturated; Fenofibrate; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Kidney Diseases; Lipids; Male; Membrane Potentials; Muscle Contraction; Muscle Fibers, Fast-Twitch; Muscle, Skeletal; Muscular Diseases; Myosin Heavy Chains; Organ Size; Pyrroles; Rats; Rats, Wistar; Rhabdomyolysis; Time Factors	2006
The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate. Journal of cardiovascular pharmacology and therapeutics, 2006, Volume: 11, Issue:3 Topics: Adult; Aged; Analysis of Variance; Apolipoprotein A-I; Apolipoproteins B; Apolipoproteins E; Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Female; Fenofibrate; Gene Frequency; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; Polymorphism, Genetic; Pyrroles; Treatment Outcome; Triglycerides	2006
Simultaneous quantitative resolution of atorvastatin calcium and fenofibrate in pharmaceutical preparation by using derivative ratio spectrophotometry and chemometric calibrations. Analytical sciences : the international journal of the Japan Society for Analytical Chemistry, 2007, Volume: 23, Issue:4 Topics: Anticholesteremic Agents; Atorvastatin; Calibration; Fenofibrate; Heptanoic Acids; Pharmaceutical Preparations; Pyrroles; Spectrophotometry, Ultraviolet	2007
Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid. Drug metabolism and disposition: the biological fate of chemicals, 2007, Volume: 35, Issue:8 Topics: Anticholesteremic Agents; Area Under Curve; Atorvastatin; Catalysis; Drug Interactions; Fenofibrate; Gemfibrozil; Glucuronic Acid; Glucuronides; Glucuronosyltransferase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lactones; Microsomes, Liver; Models, Biological; Molecular Structure; Pyrroles; Recombinant Proteins; Tandem Mass Spectrometry; Uridine Diphosphate Glucuronic Acid	2007
Efficacy of lipid-lowering medications in patients treated with clozapine: a naturalistic study. Journal of clinical psychopharmacology, 2008, Volume: 28, Issue:3 Topics: Adult; Antipsychotic Agents; Atorvastatin; Cholesterol; Clozapine; Female; Fenofibrate; Gemfibrozil; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Psychotic Disorders; Pyrroles; Retrospective Studies; Schizophrenia; Treatment Outcome; Triglycerides	2008
Stability indicating UPLC method for simultaneous determination of atorvastatin, fenofibrate and their degradation products in tablets. Journal of pharmaceutical and biomedical analysis, 2008, Sep-10, Volume: 48, Issue:1 Topics: Anticholesteremic Agents; Atorvastatin; Buffers; Chromatography, High Pressure Liquid; Drug Contamination; Drug Stability; Fenofibrate; Heptanoic Acids; Hydrogen-Ion Concentration; Molecular Structure; Pyrroles; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Tablets; Time Factors	2008
Kinetic studies of the metabolism of rapidly exchangeable apolipoproteins may leave investigators and readers with exchangeable results. Arteriosclerosis, thrombosis, and vascular biology, 2008, Volume: 28, Issue:10 Topics: Apolipoprotein C-III; Apolipoproteins; Apolipoproteins A; Apolipoproteins B; Atorvastatin; Cholesterol; Down-Regulation; Dyslipidemias; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kinetics; Lipoproteins, VLDL; Male; Metabolic Syndrome; Pyrroles; Research Design; Treatment Outcome; Triglycerides	2008
Comparison of treatment of severe high-density lipoprotein cholesterol deficiency in men with daily atorvastatin (20 mg) versus fenofibrate (200 mg) versus extended-release niacin (2 g). The American journal of cardiology, 2008, Nov-15, Volume: 102, Issue:10 Topics: Adult; Aged; Atorvastatin; Cholesterol, HDL; Deficiency Diseases; Fenofibrate; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Middle Aged; Niacin; Pilot Projects; Pyrroles; Severity of Illness Index	2008
Pharmacoeconomic analysis of hypertriglyceridemia treatment at medical institutions. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2008, Volume: 128, Issue:12 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cohort Studies; Cost-Benefit Analysis; Economics, Pharmaceutical; Fenofibrate; Health Facilities; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Pyrroles; Triglycerides	2008
Statins and fenofibrate affect skeletal muscle chloride conductance in rats by differently impairing ClC-1 channel regulation and expression. British journal of pharmacology, 2009, Volume: 156, Issue:8 Topics: Action Potentials; Animals; Atorvastatin; Benzophenanthridines; Calcium; Cell Line; Chloride Channels; Chlorides; Dose-Response Relationship, Drug; Down-Regulation; Electromyography; Enzyme Activation; Fatty Acids, Monounsaturated; Fenofibrate; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Male; Muscle, Skeletal; Patch-Clamp Techniques; Protein Kinase C; Protein Kinase Inhibitors; Pyrroles; Rats; Rats, Wistar; RNA, Messenger; Transfection	2009
Unexpected and abnormally low HDL cholesterol levels on combination hypolipidemic therapy. The Journal of the Association of Physicians of India, 2009, Volume: 57 Topics: Atorvastatin; Cholesterol, HDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Middle Aged; Pyrroles	2009
Serum adiponectin is decreased in patients with familial combined hyperlipidemia and normolipaemic relatives and is influenced by lipid-lowering treatment. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2009, Volume: 19, Issue:9 Topics: Adiponectin; Adult; Age Distribution; Atorvastatin; Biomarkers; Cholesterol, HDL; Family; Female; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Insulin Resistance; Male; Middle Aged; Phenotype; Prevalence; Pyrroles; Randomized Controlled Trials as Topic; Waist Circumference; Young Adult	2009
Heparin treatment for severe hypertriglyceridemia in diabetic ketoacidosis. Archives of internal medicine, 2009, Aug-10, Volume: 169, Issue:15 Topics: Atorvastatin; Cholesterol; Diabetic Ketoacidosis; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Omega-3; Fenofibrate; Half-Life; Heparin; Heptanoic Acids; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Infusions, Intravenous; Insulin; Male; Middle Aged; Pancreatitis, Acute Necrotizing; Pyrroles; Triglycerides	2009
Atorvastatin and fenofibrate increase apolipoprotein AV and decrease triglycerides by up-regulating peroxisome proliferator-activated receptor-alpha. British journal of pharmacology, 2009, Volume: 158, Issue:3 Topics: Animals; Apolipoprotein A-V; Apolipoproteins; Atorvastatin; Cell Line, Tumor; Drug Synergism; Fenofibrate; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Liver; Male; PPAR alpha; Pyrroles; Rats; Rats, Sprague-Dawley; Triglycerides; Up-Regulation	2009
Statins and fibrate target ClC-1 - from side effects to CLC pharmacology. British journal of pharmacology, 2009, Volume: 156, Issue:8 Topics: Action Potentials; Animals; Atorvastatin; Calcium; Chloride Channels; Chlorides; Down-Regulation; Enzyme Activation; Fatty Acids, Monounsaturated; Fenofibrate; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Muscle, Skeletal; Protein Kinase C; Pyrroles; RNA, Messenger	2009
Concerns about heparin therapy for hypertriglyceridemia. Archives of internal medicine, 2010, Jan-11, Volume: 170, Issue:1 Topics: Atorvastatin; Cholesterol; Chylomicrons; Diabetic Ketoacidosis; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Omega-3; Fenofibrate; Half-Life; Heparin; Heptanoic Acids; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Infusions, Intravenous; Insulin; Male; Middle Aged; Pancreatitis, Acute Necrotizing; Pyrroles; Triglycerides	2010
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2010, Volume: 10, Issue:2 Topics: Aged; Atorvastatin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2010
Comparison of fibrate, ezetimibe, low- and high-dose statin therapy for the dyslipidemia of the metabolic syndrome in a mouse model. Angiology, 2011, Volume: 62, Issue:2 Topics: Animals; Atorvastatin; Azetidines; Disease Models, Animal; Dose-Response Relationship, Drug; Dyslipidemias; Ezetimibe; Fenofibrate; Heptanoic Acids; Hypolipidemic Agents; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Pyrroles	2011
Disappearance of angina pectoris by lipid-lowering in type III hyperlipoproteinemia. The American journal of cardiology, 2011, Mar-01, Volume: 107, Issue:5 Topics: Angina Pectoris; Atorvastatin; Drug Therapy, Combination; Electrocardiography; Exercise Test; Female; Fenofibrate; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipoproteinemia Type III; Hypolipidemic Agents; Middle Aged; Pyrroles; Tomography, X-Ray Computed	2011
Not a graves' situation. The American journal of medicine, 2011, Volume: 124, Issue:3 Topics: Atorvastatin; Biomarkers; Diagnosis, Differential; Drug Therapy, Combination; Eye Diseases; Fenofibrate; Graves Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Oculomotor Muscles; Pyrroles; Thyroid Gland	2011
[A dyslipidemia animal model induced by poloxamer 407 in golden hamsters and pilot study on the mechanism]. Yao xue xue bao = Acta pharmaceutica Sinica, 2011, Volume: 46, Issue:4 Topics: Animals; Anticholesteremic Agents; Atorvastatin; CD36 Antigens; Cricetinae; Disease Models, Animal; Dyslipidemias; Fenofibrate; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipid Metabolism; Liver; Male; Malondialdehyde; Mesocricetus; Nitric Oxide; Phosphatidylcholine-Sterol O-Acyltransferase; Poloxamer; PPAR alpha; Pyrroles; RNA, Messenger; Superoxide Dismutase	2011
Altered fibrin clot properties in patients with retinal vein occlusion. Journal of thrombosis and haemostasis : JTH, 2011, Volume: 9, Issue:12 Topics: C-Reactive Protein; Coronary Artery Disease; Female; Fenofibrate; Fibrin; Fibrinolysis; Heptanoic Acids; Homocysteine; Humans; Hypersensitivity, Immediate; Laser Coagulation; Lipoprotein(a); Male; Pyrroles; Retinal Vein; Retinal Vein Occlusion; Simvastatin; Tetrahydroisoquinolines; Thrombosis; Venous Thromboembolism; Venous Thrombosis	2011
Atorvastatin and fenofibric acid differentially affect the release of adipokines in the visceral and subcutaneous cultures of adipocytes that were obtained from patients with and without mixed dyslipidemia. Pharmacological reports : PR, 2011, Volume: 63, Issue:5 Topics: Adipocytes; Adipokines; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Cells, Cultured; Drug Therapy, Combination; Dyslipidemias; Enzyme-Linked Immunosorbent Assay; Female; Fenofibrate; Heptanoic Acids; Humans; In Vitro Techniques; Intra-Abdominal Fat; Male; Middle Aged; Pyrroles; Subcutaneous Fat	2011
Managing dyslipidaemia: evolving role of combination therapy. Journal of the Indian Medical Association, 2011, Volume: 109, Issue:8 Topics: Atorvastatin; Azetidines; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Niacin; Pyrroles	2011
An unusual cause of delayed puberty: Berardinelli- Seip syndrome. Journal of pediatric endocrinology & metabolism : JPEM, 2012, Volume: 25, Issue:11-12 Topics: Administration, Cutaneous; Adolescent; Atorvastatin; Combined Modality Therapy; Diet, Fat-Restricted; Drug Therapy, Combination; Estrogens; Exercise Therapy; Female; Fenofibrate; Fish Oils; Heptanoic Acids; Humans; Hypertension, Portal; Hypertriglyceridemia; Insulin; Insulin Resistance; Lipodystrophy, Congenital Generalized; Pioglitazone; Propranolol; Puberty, Delayed; Pyrroles; Thiazolidinediones; Treatment Outcome	2012
Comparative effectiveness of fish oil versus fenofibrate, gemfibrozil, and atorvastatin on lowering triglyceride levels among HIV-infected patients in routine clinical care. Journal of acquired immune deficiency syndromes (1999), 2013, Nov-01, Volume: 64, Issue:3 Topics: Adult; Alabama; Atorvastatin; California; CD4-Positive T-Lymphocytes; Cohort Studies; Comparative Effectiveness Research; Drug Interactions; Female; Fenofibrate; Fish Oils; Gemfibrozil; Heptanoic Acids; HIV Infections; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; North Carolina; Practice Guidelines as Topic; Pyrroles; Retrospective Studies; San Francisco; Treatment Outcome; Triglycerides; Washington	2013
APOE3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome. Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:6* Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Apolipoprotein E3; Atorvastatin; Cholesterol Ester Transfer Proteins; Disease Models, Animal; Fenofibrate; Glucagon-Like Peptide 1; Heptanoic Acids; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Liraglutide; Male; Metabolic Syndrome; Mice, Transgenic; Niacin; Non-alcoholic Fatty Liver Disease; Obesity; Pyrroles; Rosiglitazone; Thiazolidinediones	2014
Eicosapentaenoic acid inhibits glucose-induced membrane cholesterol crystalline domain formation through a potent antioxidant mechanism. Biochimica et biophysica acta, 2015, Volume: 1848, Issue:2 Topics: Antioxidants; Atorvastatin; Cholesterol, LDL; Eicosapentaenoic Acid; Fenofibrate; Gemfibrozil; Glucose; Heptanoic Acids; Lipid Peroxidation; Lipid Peroxides; Membrane Lipids; Membranes, Artificial; Niacin; Pyrroles	2015
Thioredoxin interacting protein mediates lipid-induced impairment of glucose uptake in skeletal muscle. Biochemical and biophysical research communications, 2016, Oct-28, Volume: 479, Issue:4 Topics: AMP-Activated Protein Kinases; Animals; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Biological Transport, Active; Carrier Proteins; Cell Line; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Fenofibrate; Glucose; Glucose Transporter Type 4; Insulin Resistance; Mice; Muscle Fibers, Skeletal; Nuclear Proteins; Palmitic Acid; Phenylpropionates; Pyrroles; Reactive Oxygen Species; Sirtuin 1; Thioredoxins; Transcription Factors	2016
Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models. Liver international : official journal of the International Association for the Study of the Liver, 2018, Volume: 38, Issue:6 Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Biomarkers; Diet, High-Fat; Fenofibrate; Hep G2 Cells; Humans; Kupffer Cells; Liver; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Phenylpropionates; Pioglitazone; PPAR alpha; Pyrroles; Tumor Necrosis Factor-alpha	2018